In the latest episode of The Retina TL;DR with Dr. Weng—Part 2 of a special two-part series—host Christina Y. Weng, MD, MBA, FASRS, sits down with two more of her former residents for candid advice on transitioning into fellowship, balancing research and family, and what excites them most about the future of retina.
In a single day, the FDA cleared the first nonprescription apraclonidine drop, the first at-home subcutaneous therapy for thyroid eye disease, and a presbyopia indication for an established pupil-modulating drop.